Print
Orchid Chemicals & Pharmaceuticals Ltd.
Unaudited Financial Results of Three Months Ended June 30, 2005
       
(Rs.Lakhs)
S.No
Particulars
Three Months ended
30-June-05
(unaudited)
Three Months ended
30-June-04
(unaudited)
Year ended31-Mar-05
(Audited)
1
 Sales and Operating Income
17025.75
17386.43
68929.44
2
 Other Income
43.82
40.12
82.24
3
 Total Expenditure
12483.54
13702.51
52700.71

a) Decrease/(Increase) in Stock in trade
(2329.19)
24.73
(9837.95)
b) Consumption of raw materials
9391.23
8787.67
39400.50
c) Staff Cost
1408.39
1226.97
5438.09
d) Other Expenditure
4013.11
3663.14
17700.07
4
Profit before Interest, Depreciation & Tax (1+2-3)
4586.03
3724.04
16310.97
5
 Interest and Finance Charges
2076.12
1686.27
7231.00
6
 Depreciation
1690.53
1529.26
6189.20
7

Profit before tax
(4-5-6)
819.38
508.51
2890.77
8
 Provision for Taxation
  Current Tax
46.00
39.09
194.60
  Deferred Tax
-
-
(404.93)
  Fringe Benefit Tax
40.00
-
-
9
 Net Profit (7-8)
733.38
469.42
3101.10
10
 Paid- up Equity Share Capital (Face value of Rs. 10 each)
3414.37
3238.19
3413.19
11
 Reserves excluding Revaluation Reserves
43714.20
12
 Basic Earnings per Share (EPS) Rs.
2.15*
1.45*
9.53
13
 Diluted Earnings per share (EPS) Rs.
2.13*
1.38*
9.05
 

 

      
Segment wise Revenue, Results and Capital Employed

 

    

 

(Rs.Lakhs)
S.No
Particulars
Three Months ended
30-June-05
Three Months
ended
30-June-04
Year ended
31-Mar-05
1
 Segment Revenue

 
  a) Bulk
14668.12
15054.31
60092.68
  b) Formulations
3498.42
2481.69
9620.20
  Total
18166.54
17536.00
69712.88
  Less: Inter segment revenue
1140.79
149.57
783.44
  Net Sales / Income from Operations
17025.75
17386.43
68929.44
2
 Segment Results
  a) Bulk
2555.63
2109.44
9999.90
  b) Formulations
296.05
45.22
39.63
  Total
2851.68
2154.66
10039.53
  Less: i) Interest (Net)
2076.12
1686.27
7231.00
  ii) Other unallocable expenditure net off unallocable income
(43.82)
(40.12)
(82.24)
  Total Profit Before Tax
819.38
508.51
2890.76
3
 Capital Employed
  a) Bulk
126005.00
108937.65
127174.23
  b) Formulations
33900.25
15961.63
21739.24
  Total
159905.25
124899.28
148913.47
         
* EPS is for the period (not annualised) after providing for taxes
 
1
 The above financial results were taken on record by the Board of Directors at its meeting held on Monday, July 18, 2005.
2
 The above accounts have been subjected to Limited Review by the Statutory Auditors.
3
 Figures for the previous periods have been regrouped wherever necessary.
4
 During the quarter, the Cephalosporin generic formulations facility at Irungattukottai near Chennai was commissioned.
5
 During the quarter, Orchid Research Laboratories Limited, India became the wholly owned subsidiary of the Company
6
 The Board has approved the issue of Bonus shares in the ratio of one bonus share to two shares held.
7
 The Company received 11 complaints during the quarter ended June 30, 2005 from the shareholders, all the complaints have been resolved and no complaints were pending as on June 30, 2005.
 
 
for and on behalf of the Board

Place : Chennai
Date : July 18, 2005

K. Raghavendra Rao
Managing Director